Inhibrx, Inc. (NASDAQ:INBX) Sees Large Increase in Short Interest

Inhibrx, Inc. (NASDAQ:INBX) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,200,000 shares, a growth of 10.1% from the November 30th total of 1,090,000 shares. Currently, 12.1% of the shares of the stock are short sold. Based on an average trading volume of 77,600 shares, the short-interest ratio is currently 15.5 days.

Inhibrx Price Performance

NASDAQ:INBX opened at $15.14 on Tuesday. The company’s 50-day moving average price is $15.12 and its 200-day moving average price is $14.64. Inhibrx has a twelve month low of $10.80 and a twelve month high of $18.95.

Insider Activity at Inhibrx

In other news, Director Jon Faiz Kayyem bought 69,686 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average price of $14.23 per share, with a total value of $991,631.78. Following the completion of the transaction, the director now directly owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. The trade was a -374.80 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.20% of the stock is currently owned by corporate insiders.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.